Diabetes News

TV watching in excess of 1 hour per day was associated with increased risk for atherosclerotic heart disease, independent of genetic risk for diabetes, according to new data published in the Journal of the American Heart Association.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial.

Slightly elevated blood glucose within a range of what is generally considered “normal” may be associated with increased risk for heart disease, researchers reported.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes compared with dipeptidyl peptidase 4 inhibitors, results of a target trial emulation study suggested.

The American Board of Medical Specialties denied approval of creation of an independent cardiology certification board championed by the American Board of Cardiovascular Medicine, according to a press release.

Most adults in the United States with physical chronic health conditions manage them at work but have not told their employer about them, results from a national survey showed.

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor stroke or transient ischemic attack, a speaker reported.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health issues, recent data suggest they may improve brain health.